Search results | squibb


Partnering Agreements with Bristol-Myers Squibb

This report provides all the information you require to better understand Bristol-Myers Squibb and its partnering interests and activities over the past seven years.


Bristol-Myers Squibb

Bristol-Myers Squibb (BMS) is a top pharmaceutical company based in New York, NY, USA.

Bristol-Myers Squibb: Company profile

Bristol-Myers Squibb, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Bristol-Myers Squibb: M&A activity 2005-2013

Bristol-Myers Squibb (BMS) has announced 9 M&A deals since 2005, with the lead deals being the acquisitions of Amylin, Inhibitex and Medarex

Partnering with Bristol-Myers Squibb: String of Pearls approach to partnering

Bristol-Myers Squibb (BMS) is a top pharmaceutical company discovery, development and commercialization of medicinal products worldwide

Bristol-Myers Squibb: Partnering activity 2005-2013

Bristol-Myers Squibb announced over 160 partnering / licensing deals since 2005, with over 30 deals in 2012 alone

Bristol-Myers Squibb eyes big deal, biotech rumour mill

Biotech rumour mill: If AstraZeneca, a big pharma company, decides it needs a big acquisition to get out of the doldrums, it may find itself competing with Bristol-Myers Squibb

Dealmakers weekly review – July 3 2012 – Amylin, Bristol-Myers Squibb, AstraZeneca, Biogen Idec, Celgene, Inhibrx

BMS acquires Amylin and then collabroates with AstraZeneca on diabetes franchise dominates the weeks dealmaking

Amylin shares rocket up on report of $3.5 billion buyout offer by Bristol-Myers Squibb

Amylin Pharmaceuticals Inc., maker of the diabetes drug Bydureon, may draw bids from other suitors after rejecting a $3.5 billion unsolicited takeover offer from Bristol-Myers Squibb Co. earlier this year.

Drugmakers including Achillion Pharmaceuticals and Bristol-Myers Squibb seek deals to gain share of future Hep C combo pill

Written by Ryan Flinn and Drew Armstrong for Bloomberg. A developing medical theory that hepatitis C can be overcome with the same type of drug cocktails that tamed HIV may drive acquisition strategies as companies try to anticipate which products work best with other medicines.

Bristol-Myers Squibb to acquire ZymoGenetics for $885 million

Global biopharmaceutical company Bristol-Myers Squib has today announced that is has made an $885 million offer to acquire ZymoGenetics for a total of $885 million in cash.


Sorry, your search returned no results.


Manufacturing agreement for biologics between Bristol-Myers Squibb and Lonza

Bristol-Myers Squibb Company and Lonza announced a multi-year expansion of their existing biologics manufacturing agreement.

Phama alliance between Immuneering and Bristol-Myers Squibb

Immuneering Corporation has entered into a pharma alliance agreement to expand its existing relationship with Bristol-Myers Squibb for the use of Immuneering’s proprietary computational biology methods to identify biological insights that may facilitate discovery and development of medicines.

Bristol-Myers Squibb and IncellDx enter into a pharma partnering

IncellDx have entered into an pharma partnering agreement with Bristol-Myers Squibb Company to the development of an assay for potential application in a molecular companion diagnostic.

Bristol-Myers Squibb expands big pharma deals with Simcere Pharmaceuticals for BMS-795311 co-development

Bristol-Myers Squibb Company and Simcere Pharmaceutical have expanded their pharma deals formed in 2010.

Bristol-Myers Squibb eyes big deal, biotech rumour mill

Biotech rumour mill: If AstraZeneca, a big pharma company, decides it needs a big acquisition to get out of the doldrums, it may find itself competing with Bristol-Myers Squibb

Bristol-Myers Squibb joins hands with MMRF to be pharma partners

Bristol-Myers Squibb, a big pharma company & Multiple Myeloma Research Foundation (MMRF) have signed a deal to be pharma partners.

Bristol-Myers Squibb & the Medicines Company makes news with pharma partnering deal

Bristol-Myers Squibb, a big biopharma/ biotech establishment has signed a global pharma partnering pact with The Medicines Company

Bristol-Myers Squibb grabs pharma partners deal to Biocon’s oral insulin amid diabetes growth

In a pharma partners agreement, Biocon & Bristol-Myers Squibb, both top biotech/pharma companies, have agreed to sign on a licensing deal for its experimental biopharmaceutical drug IN-105, which is an orally administered insulin.

Portola snaps pharma partnering deal with two pharma giants, Bristol-Myers Squibb & Pfizer

Portola Pharmaceuticals, Bristol-Myers Squibb Company and Pfizer announced a pharma partnering clinical collaboration agreement to conduct a proof-of-concept study of PRT4445 and the investigational oral Factor Xa inhibitor ELIQUIS(apixaban)

Bristol-Myers Squibb pharma alliances with Vanderbilt University for Parkinson’s research

Vanderbilt University and Bristol-Myers Squibb, a top big pharma company have signed a pharma alliances agreement for the discovery, development and commercialization of novel therapies acting on the mGluR4 glutamate receptor, known as positive allosteric modulators or PAMs, for the treatment of Parkinson’s disease